Wells Fargo upgrades Praxis Precision Medicines stock to Overweight
Published on 11/19/2026 at 04:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst confidence improves
- Wells Fargo upgraded Praxis Precision Medicines after reassessing the robustness of Ulixacaltamide data.
- The company is approaching regulatory decisions for two late-stage CNS programs.
- Praxis is expanding its pipeline beyond epilepsy and essential tremor.
Wells Fargo upgraded Praxis Precision Medicines stock from Equal Weight to Overweight on Tuesday, November 17, 2026, and raised its price target to USD 509 from USD 343. Investing.com reported that the broker became less concerned about the robustness of the primary endpoint for Ulixacaltamide after discussions following Praxis' Investor Day.
Wells Fargo changes its view
Wells Fargo had previously questioned the strength of the primary endpoint and the limited information available on an alternative titration protocol. The firm said additional analyses shared with the FDA, including a prespecified intent-to-treat tipping-point analysis, supported a similar efficacy picture to the modified intent-to-treat analysis.
The broker also cited positive feedback from key opinion leaders and said the added analyses strengthened its view that Ulixacaltamide's treatment effect is real. Wells Fargo said Praxis considers it very likely that the alternative protocol will appear on the product label.
Regulatory milestones shape outlook
Praxis is developing treatments for central nervous system disorders and is preparing potential launches for Ulixacaltamide in essential tremor and relutrigine in developmental and epileptic encephalopathies. The company is also advancing additional programs in movement disorders, pain, epilepsy and antisense oligonucleotides.
For investors, the revised rating highlights how clinical-data interpretation and regulatory progress are driving the near-term outlook. The remaining catalyst is the FDA's review of Praxis' late-stage candidates, while the broader pipeline offers longer-term opportunities but also carries development risk.
Praxis builds a CNS portfolio
Praxis Precision Medicines is a Boston-based biopharmaceutical company focused on central nervous system therapies. It uses the Cerebrum small-molecule platform and the Solidus antisense oligonucleotide platform to develop treatments for rare and more prevalent neurological disorders. Its portfolio spans epilepsy and movement disorders, with four late-stage product candidates.
Praxis Precision Medicines at a glance
- Company: Praxis Precision Medicines, Inc.
- Ticker: PRAX
- Exchange: Nasdaq
- Sector: CNS precision neuroscience biotechnology
- Latest rating action: November 17, 2026
The company operates within the broader US market, tracked through the S&P 500 market environment.
